JP6812360B2 - 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 - Google Patents

嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 Download PDF

Info

Publication number
JP6812360B2
JP6812360B2 JP2017553076A JP2017553076A JP6812360B2 JP 6812360 B2 JP6812360 B2 JP 6812360B2 JP 2017553076 A JP2017553076 A JP 2017553076A JP 2017553076 A JP2017553076 A JP 2017553076A JP 6812360 B2 JP6812360 B2 JP 6812360B2
Authority
JP
Japan
Prior art keywords
amisulpride
antiemetic
unit dose
kit
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510898A5 (enExample
JP2018510898A (ja
Inventor
クライブ ギルバート，ジュリアン
クライブ ギルバート，ジュリアン
ウィリアム グリストウッド，ロバート
ウィリアム グリストウッド，ロバート
フォックス，ガブリエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of JP2018510898A publication Critical patent/JP2018510898A/ja
Publication of JP2018510898A5 publication Critical patent/JP2018510898A5/ja
Application granted granted Critical
Publication of JP6812360B2 publication Critical patent/JP6812360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017553076A 2015-04-10 2016-04-11 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用 Active JP6812360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506116.1A GB201506116D0 (en) 2015-04-10 2015-04-10 Kit and combination therapy for nausea and vomiting
GB1506116.1 2015-04-10
PCT/GB2016/050998 WO2016162695A1 (en) 2015-04-10 2016-04-11 Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Publications (3)

Publication Number Publication Date
JP2018510898A JP2018510898A (ja) 2018-04-19
JP2018510898A5 JP2018510898A5 (enExample) 2019-04-18
JP6812360B2 true JP6812360B2 (ja) 2021-01-13

Family

ID=53333601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017553076A Active JP6812360B2 (ja) 2015-04-10 2016-04-11 嘔気嘔吐を治療するためのアミスルプリドと他の制吐薬との併用

Country Status (22)

Country Link
US (1) US10322106B2 (enExample)
EP (1) EP3280392B1 (enExample)
JP (1) JP6812360B2 (enExample)
KR (2) KR102711661B1 (enExample)
CN (1) CN107872975A (enExample)
AU (1) AU2016246104B2 (enExample)
CA (1) CA2982251C (enExample)
CY (1) CY1124184T1 (enExample)
DK (1) DK3280392T3 (enExample)
ES (1) ES2866933T3 (enExample)
GB (1) GB201506116D0 (enExample)
HR (1) HRP20210624T1 (enExample)
HU (1) HUE054165T2 (enExample)
IL (2) IL295650A (enExample)
LT (1) LT3280392T (enExample)
MX (1) MX388735B (enExample)
PL (1) PL3280392T3 (enExample)
PT (1) PT3280392T (enExample)
RS (1) RS61760B1 (enExample)
SI (1) SI3280392T1 (enExample)
SM (1) SMT202100216T1 (enExample)
WO (1) WO2016162695A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618425D0 (en) * 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
AU2018379992B2 (en) 2017-12-05 2022-07-21 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
JP2026526054A (ja) 2023-07-13 2026-08-04 アコンカグア・バイオ・インコーポレイテッド 化合物、組成物、および方法
EP4743174A1 (en) 2023-07-13 2026-05-20 Aconcagua Bio, Inc. CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS
EP4771001A1 (en) 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026096926A1 (en) 2024-11-01 2026-05-07 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2026156091A1 (en) 2025-01-15 2026-07-23 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003962D0 (en) 2010-03-10 2010-04-21 Tangentix Ltd Multimedia content delivery system
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
WO2013040164A1 (en) * 2011-09-13 2013-03-21 Biomed Valley Discoveries, Inc. Compositions and methods for treating metabolic disorders

Also Published As

Publication number Publication date
SMT202100216T1 (it) 2021-05-07
GB201506116D0 (en) 2015-05-27
SI3280392T1 (sl) 2021-08-31
KR20240125705A (ko) 2024-08-19
ES2866933T3 (es) 2021-10-20
DK3280392T3 (da) 2021-03-08
CA2982251C (en) 2023-06-13
LT3280392T (lt) 2021-04-26
JP2018510898A (ja) 2018-04-19
IL295650A (en) 2022-10-01
HUE054165T2 (hu) 2021-08-30
RS61760B1 (sr) 2021-05-31
HRP20210624T1 (hr) 2021-05-28
US20180071249A1 (en) 2018-03-15
PT3280392T (pt) 2021-03-12
EP3280392A1 (en) 2018-02-14
AU2016246104A1 (en) 2017-11-30
MX388735B (es) 2025-03-20
US10322106B2 (en) 2019-06-18
HK1250913A1 (en) 2019-01-18
CA2982251A1 (en) 2016-10-13
PL3280392T3 (pl) 2021-10-18
WO2016162695A1 (en) 2016-10-13
CN107872975A (zh) 2018-04-03
KR102711661B1 (ko) 2024-10-02
CY1124184T1 (el) 2022-07-22
KR20180016350A (ko) 2018-02-14
MX2017012991A (es) 2018-02-01
EP3280392B1 (en) 2021-02-24
AU2016246104B2 (en) 2018-12-13
IL254929A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
KR102711661B1 (ko) 구역과 구토를 치료하기 위한 아미설프리드 및 추가의 구토 방지제의 병용
TWI595873B (zh) 用於治療中樞誘發噁心及嘔吐之組成物及方法
AU2011225898B2 (en) The use of amisulpride as an anti-emetic
JP2013511507A (ja) 中枢を介する悪心および嘔吐を治療するための組成物および方法関連出願の相互参照本出願は、２００９年１１月１８日に出願された米国仮特許出願第６１／２６２，４７０号および２０１０年９月１４日に出願された米国仮特許出願第６１／３８２，７０９号の利益を主張する。これらの出願第６１／２６２，４７０号および第６１／３８２，７０９号は、参照により本明細書に全体として組み込まれる。
JP7526244B2 (ja) 術後悪心嘔吐の救援治療
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
JP2020506209A5 (enExample)
CA3052535C (en) Rescue treatment of post operative nausea and vomiting
HK1250913B (en) Dosage regimens of amisulpride for treating nausea and vomiting
EA042759B1 (ru) Экстренное лечение постоперационной тошноты и рвоты
HK40013552A (en) Rescue treatment of post operative nausea and vomiting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201216

R150 Certificate of patent or registration of utility model

Ref document number: 6812360

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250